The African region’s potential in biotech is attracting the attention of pharmaceutical companies, leading to a surge in collaborative efforts and research partnerships. It is crucial that we seize this momentum to stem a talent exodus and create opportunities in the scientific sector for health outcomes.
Africa's rich genetic diversity has been the subject of increasing scientific interest, and genetic research conducted across the continent holds immense value for the entire world. Studies have shown that genetic variations among populations can significantly impact how individuals respond to drugs and treatments. However, most available genetic data comes from just three countries — the U.K., with 40.5%; the U.S., with 19%; and Iceland, with 12%, leaving a substantial knowledge gap regarding genetic factors in other populations, including Africans. By predominantly relying on research conducted on European ancestry, we risk missing out on crucial insights that could cover a significant part of the global population.
The rise in healthy life expectancy in Africa has brought attention to the growing burden of noncommunicable diseases like cancer. These diseases are becoming major public health concerns in the region. In fact, estimates show that cancer cases in sub-Saharan Africa will nearly double over the next 20 years. Therefore, the need for precision medicine that tailors treatments and targets therapies based on sub-Saharan African ancestry is vital. Understanding the unique genetic makeup of sub-Saharan African communities can help us design treatments that radically change the range, nature, and scope of health care options.
About the author
Dr. Yaw Bediako
Dr. Yaw Bediako is an immunologist, founder and chief executive officer of Yemaachi Biotechnology, and researcher at the West African Centre for Cell Biology and Infectious Pathogens (WACCBIP), University of Ghana.
